<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fosphenytoin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01320</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01320/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01320/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01320.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01320.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01320.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01320.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01320.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01320">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(3-Phosphoryloxymethyl)phenytoin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Fosfenitoina</td><td>Spanish</td><td>INN</td></tr><tr><td>Fosphenytoine</td><td>French</td><td>INN</td></tr><tr><td>Fosphenytoinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fosphenytoin sodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000296/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000296/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: GQPXYJNXTAFDLT-UHFFFAOYSA-L</li>
              <li>Monoisotopic Mass: 406.03066202</li>
              <li>Average Mass: 406.2375</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000296">DBSALT000296</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cerebyx</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prodilantin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li></ul></td></tr><tr><th>CAS number</th><td>93390-81-9</td></tr><tr><th>Weight</th><td>Average: 362.2739<br>Monoisotopic: 362.066772734</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>O<sub>6</sub>P</td></tr><tr><th>InChI Key</th><td>XWLUWCNOOVRFPX-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">[(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methoxy]phosphonic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azolidines</td></tr><tr><th>Subclass</th><td>Imidazolidines</td></tr><tr><th>Direct parent</th><td>Phenylhydantoins</td></tr><tr><th>Alternative parents</th><td>Diphenylmethanes; Phenylimidazolidines; Ureides; Organic Phosphoric Acids; N-substituted Carboxylic Acid Imides; Organophosphate Esters; Tertiary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>phenylimidazolidine; ureide; phosphoric acid ester; carboxylic acid imide, n-substituted; organic phosphate; benzene; tertiary carboxylic acid amide; tertiary amine; carboxamide group; polyamine; carboxylic acid derivative; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin.</td></tr><tr><th>Pharmacodynamics</th><td>Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. Following parenteral administration of fosphenytoin, fosphenytoin is converted to the anticonvulsant phenytoin by endogenous phosphatases. For every mmol of fosphenytoin administered, one mmol of phenytoin is produced. The pharmacological and toxicological effects of fosphenytoin include those of phenytoin.</td></tr><tr><th>Mechanism of action</th><td>Fosphenytoin is a prodrug of phenytoin and accordingly, its anticonvulsant effects are attributable to phenytoin. Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas.</td></tr><tr><th>Absorption</th><td>Fosphenytoin is completely bioavailable following lM administration.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>4.3 to 10.8 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Extensively bound (95% to 99%) to human plasma proteins, primarily albumin.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Fosphenytoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01170">Phenytoin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1305">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Phenytoin derived from administration of Cerebyx is extensively metabolized in the liver and excreted in urine primarily as 5-(p-hydroxyphenyl)-5-phenylhydantoin and its glucuronide; little unchanged phenytoin (1%&#8211;5% of the Cerebyx dose) is recovered in urine.</td></tr><tr><th>Half life</th><td>Fosphenytoin has a half-life of approximately 15 minutes.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Nausea, vomiting, lethargy, tachycardia, bradycardia, asystole, cardiac arrest, hypotension, syncope, hypocalcemia, metabolic acidosis, and death have been reported in cases of overdosage with fosphenytoin. The median lethal dose of fosphenytoin given intravenously in mice and rats was 156 mg PE/kg and approximately 250 mg PE/kg, or about 0.6 and 2 times, respectively, the maximum human loading dose on a mg/m2 basis. Signs of acute toxicity in animals included ataxia, labored breathing, ptosis, and hypoactivity.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Fosphenytoin (Antiarrhythmic) Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00326?highlight%5Bcompounds%5D%5B%5D=DB01320&amp;highlight%5Bproteins%5D%5B%5D=DB01320">SMP00326</a></td></tr><tr><td>Fosphenytoin (Antiarrhythmic) Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00618?highlight%5Bcompounds%5D%5B%5D=DB01320&amp;highlight%5Bproteins%5D%5B%5D=DB01320">SMP00618</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.5244</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9215</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.639</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7952</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8466</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8731</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7094</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6873</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8477</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7802</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8859</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7169</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7672</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9083</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.614
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7835
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9674
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4215 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9578
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7299
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Parke davis div warner lambert co</li>
<li>Akorn strides llc</li>
<li>Apotex inc richmond hill</li>
<li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hikma farmaceutica (portugal) sa</li>
<li>Hospira inc</li>
<li>Luitpold pharmaceuticals inc</li>
<li>Pharmaforce inc</li>
<li>Strides arcolab limited</li>
<li>Sun pharma global inc</li>
<li>Teva parenteral medicines inc</li>
<li>Wockhardt ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.generamedix.com">Generamedix Inc.</a></li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaforceinc.com">Pharmaforce Inc.</a></li>
<li><a href="http://www.stridesarco.com">Strides Arcolab Limited</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Liquid</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Cerebyx 500 mg pe/10 ml vial</td><td>8.63USD</td><td>ml</td></tr><tr><td>Fosphenytoin 500 mg pe/10 ml</td><td>0.61USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.45e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.08</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.67</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.4</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>1.46</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-9.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>116.17</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>87.05</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>33.23</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Volker Kirsch, &#8220;Process for the preparation of sodium fosphenytoin.&#8221; U.S. Patent US20050272706, issued December 08, 2005.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20050272706&amp;tbm=pts" target="_blank">US20050272706 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Johnson J, Wrenn K: Inappropriate fosphenytoin use in the ED. Am J Emerg Med. 2001 Jul;19(4):293-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11447516">Pubmed</a></li>
	<li>Applebaum J, Levine J, Belmaker RH: Intravenous fosphenytoin in acute mania. J Clin Psychiatry. 2003 Apr;64(4):408-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12716241">Pubmed</a></li>
	<li>McCleane GJ: Intravenous infusion of fosphenytoin produces prolonged pain relief: a case report. J Pain. 2002 Apr;3(2):156-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14622802">Pubmed</a></li>
	<li>Browne TR, Kugler AR, Eldon MA: Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996 Jun;46(6 Suppl 1):S3-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/">Pubmed</a> 8649612</li>
	<li>Luszczki JJ: Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009 Mar-Apr;61(2):197-216. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19443931">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07840" target="_blank">C07840 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=56339" target="_blank">56339 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505168" target="_blank">46505168 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.50839.html" target="_blank">50839 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000520" target="_blank">DAP000520 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164746820" target="_blank">PA164746820 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2230988" target="_blank">2230988 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/fosphen.htm" target="_blank">http://www.rxlist.com/cgi/generic/fosphen.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/fosphenytoin.html" target="_blank">http://www.drugs.com/cdi/fosphenytoin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Fosphenytoin" target="_blank">Fosphenytoin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:12.12</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01320.pdf?1265922813">show</a>(820 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Fosphenytoin may increase the metabolism of alprazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase the effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>The CYP3A4 inducer, fosphenytoin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB00732">Atracurium</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, betamethasone.</td></tr><tr><td><a href="/drugs/DB00290">Bleomycin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01101">Capecitabine</a></td><td>Capecitabine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00958">Carboplatin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00262">Carmustine</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Increases phenytoin, modifies chloramphenicol</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Fosphenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00269">Chlorotrianisene</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, chlorotrianisene.</td></tr><tr><td><a href="/drugs/DB01114">Chlorphenamine</a></td><td>The antihistamine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the serum concentration of fosphenytoin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fosphenytoin if cimetidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin may increase the therapeutic and adverse effects of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB00882">Clomifene</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Fosphenytoin may increase the metabolism of clorazepate via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Hydantoin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00286">Conjugated Estrogens</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, conjugated estrogens.</td></tr><tr><td><a href="/drugs/DB01380">Cortisone acetate</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, cortisone acetate.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The hydantoin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The anticonvulsant, fosphenytoin, decreases the effect of delavirdine.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, dexamethasone.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Fosphenytoin may increase the metabolism of diazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB01119">Diazoxide</a></td><td>Diazoxide decreases the hydantoin effect</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr><tr><td><a href="/drugs/DB00255">Diethylstilbestrol</a></td><td>The enzyme inducer, fosphenytoin, may decrease the therapeutic effect of diethylstilbestrol.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The hydantoin decreases the effect of disopyramide</td></tr><tr><td><a href="/drugs/DB00822">Disulfiram</a></td><td>Disulfiram may increase the effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB01135">Doxacurium chloride</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The anticonvulsant, fosphenytoin, decreases the effect of doxycycline.</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB00783">Estradiol</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estradiol.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB04573">Estriol</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estriol.</td></tr><tr><td><a href="/drugs/DB00655">Estrone</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB04574">Estropipate</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estropipate.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine, when administered concomitantly with fosphenytoin, may experience a decrease in serum concentration. It is recommended to avoid this combination. </td></tr><tr><td><a href="/drugs/DB00949">Felbamate</a></td><td>Increased phenytoin levels and decreased felbamate levels</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The hydantoin decreases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the effect of hydantoin.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00544">Fluorouracil</a></td><td>Fluorouracil increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Fluoxetine increases the effect of phenytoin</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Fosphenytoin may increase the metabolism of flurazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Fluvoxamine may increase the therapeutic and adverse effects of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB00158">Folic Acid</a></td><td>Folic acid decreases the levels of hydantoin</td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>The hydantoin decreases the effect of furosemide</td></tr><tr><td><a href="/drugs/DB00996">Gabapentin</a></td><td>Gabapentin may increase the effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>The CYP3A4 inducer, fosphenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>The hydantoin decreases the levels of imatinib</td></tr><tr><td><a href="/drugs/DB00762">Irinotecan</a></td><td>The hydantoin decreases the effect of irinotecan</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid may increase the effect of phenytoin in 20% of patients.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Phenytoin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB01235">L-DOPA</a></td><td>The hydantoin decreases the effect of levodopa</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Phenytoin may reduce levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Phenytoin decreases the contraceptive effect</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Levels of both drugs are affected</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. </td></tr><tr><td><a href="/drugs/DB00643">Mebendazole</a></td><td>The hydantoin decreases the efficiency of mebendazole</td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, medroxyprogesterone.</td></tr><tr><td><a href="/drugs/DB00351">Megestrol acetate</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, megestrol.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The hydantoin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00553">Methoxsalen</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, methylprednisolone.</td></tr><tr><td><a href="/drugs/DB01336">Metocurine</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01011">Metyrapone</a></td><td>The combination renders the test invalid</td></tr><tr><td><a href="/drugs/DB00379">Mexiletine</a></td><td>The hydantoin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Fosphenytoin may increase the metabolism of midazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects</td></tr><tr><td><a href="/drugs/DB01226">Mivacurium</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00401">Nisoldipine</a></td><td>Phenytoin decreases the efficiency of nisoldipine</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00776">Oxcarbazepine</a></td><td>Oxcarbazepine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB03585">Oxyphenbutazone</a></td><td>The NSAID, oxphenbutazone, may increase the hydantoin effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB01337">Pancuronium</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01384">Paramethasone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, paramethasone.</td></tr><tr><td><a href="/drugs/DB00812">Phenylbutazone</a></td><td>The NSAID, phenylbutazone, may increase the hydantoin effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Modifications of drug levels for both agents</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>Phenytoin decreases the effect of quetiapine</td></tr><tr><td><a href="/drugs/DB04575">Quinestrol</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, quinestrol.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>The anticonvulsant, fosphenytoin, decreases the effect of quinidine.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Sertraline increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>The hydantoin decreases sirolimus levels</td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Sucralfate decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00359">Sulfadiazine</a></td><td>The sulfonamide increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00576">Sulfamethizole</a></td><td>The sulfonamide increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The hydantoin decreases the effect of tacrolimus</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Fosphenytoin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Fosphenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB04572">Thiotepa</a></td><td>Possible increase in thiotepa levels</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for adverse/toxic effects of Fosphenytoin if Ticlopidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for changes in Fosphenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00273">Topiramate</a></td><td>Increased phenytoin/decreased topiramate</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Fosphenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The strong CYP2C8 inducer, Fosphenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Fosphenytoin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Fosphenytoin may increase the metabolism of triazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>Trimethoprim increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB04571">Trioxsalen</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Fosphenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01199">Tubocurarine</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01080">Vigabatrin</a></td><td>Vigabatrin decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>The hydantoin decreases the effect of voriconazole</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>